Compare BKD & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKD | ADMA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | N/A | 2012 |
| Metric | BKD | ADMA |
|---|---|---|
| Price | $13.94 | $10.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $15.10 | ★ $28.00 |
| AVG Volume (30 Days) | 3.1M | ★ 9.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $0.08 | $27.46 |
| Revenue Next Year | $3.99 | $22.11 |
| P/E Ratio | ★ N/A | $17.49 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $6.07 | $7.21 |
| 52 Week High | $17.09 | $25.67 |
| Indicator | BKD | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 42.07 |
| Support Level | $13.30 | $7.21 |
| Resistance Level | $17.09 | $16.30 |
| Average True Range (ATR) | 0.44 | 0.61 |
| MACD | 0.03 | 0.29 |
| Stochastic Oscillator | 63.37 | 97.89 |
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.